15 April 2013Americas

Supreme Court to hear oral arguments in Myriad case

Myriad Genetics will deliver an oral argument at the US Supreme Court today (Monday, April 15) defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More on this story

Australia: the Myriad case

1 February 2013 The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues.

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

More features

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

Broad Institute wins appeal to restore CRISPR patent in Europe

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations